Spots Global Cancer Trial Database for oleclumab
Every month we try and update this database with for oleclumab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer | NCT04089553 | Prostate Cancer Metastatic Cast... | AZD4635 Oleclumab Durvalumab | 18 Years - 130 Years | AstraZeneca | |
| A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer | NCT03742102 | Triple Negative... | Durvalumab Capivasertib Oleclumab Paclitaxel Trastuzumab der... Datopotamab der... | 18 Years - 130 Years | AstraZeneca | |
| A Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer Populations With Correlation to Clinical, Molecular and Immunologic Parameters With DNA MethylaTION | NCT04262375 | Non Small Cell ... Renal Cell Carc... | Durvalumab Oleclumab | 18 Years - | University Health Network, Toronto | |
| A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer | NCT05221840 | Non-Small Cell ... | Durvalumab Oleclumab Monalizumab Placebo | 18 Years - | AstraZeneca | |
| Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma | NCT04668300 | Metastatic Angi... Metastatic Dedi... Metastatic Oste... Recurrent Angio... Recurrent Dedif... Recurrent Osteo... Refractory Dedi... Refractory Oste... | Durvalumab Oleclumab | 12 Years - | M.D. Anderson Cancer Center | |
| A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC | NCT03819465 | Metastatic Non-... | Durvalumab Danvatirsen Oleclumab MEDI5752 Pemetrexed Carboplatin Gemcitabine Cisplatin Nab-paclitaxel AZD2936 | 18 Years - 130 Years | AstraZeneca | |
| Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer: | NCT03875573 | Luminal B | Durvalumab Stereotactic Bo... Oleclumab | 18 Years - | Jules Bordet Institute | |
| A Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer Populations With Correlation to Clinical, Molecular and Immunologic Parameters With DNA MethylaTION | NCT04262375 | Non Small Cell ... Renal Cell Carc... | Durvalumab Oleclumab | 18 Years - | University Health Network, Toronto | |
| Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer | NCT04940286 | Borderline Rese... Resectable Panc... Stage IA Pancre... Stage IB Pancre... Stage IIA Pancr... Stage IIB Pancr... | Durvalumab Gemcitabine Nab-paclitaxel Oleclumab | 18 Years - | M.D. Anderson Cancer Center | |
| Durvalumab and Oleclumab in Resectable PDAC | NCT06060405 | Pancreatic Duct... | Durvalumab Oleclumab | 18 Years - | University Health Network, Toronto | |
| Durvalumab and Oleclumab in Resectable PDAC | NCT06060405 | Pancreatic Duct... | Durvalumab Oleclumab | 18 Years - | University Health Network, Toronto | |
| Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study | NCT03381274 | Carcinoma, Non-... | Oleclumab Osimertinib AZD4635 | 18 Years - 101 Years | MedImmune LLC | |
| A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2) | NCT03773666 | Muscle Invasive... | Durvalumab Oleclumab | 18 Years - | Dana-Farber Cancer Institute | |
| Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), The ARCHON-1 Trial | NCT03801902 | Locally Advance... Locally Recurre... Stage II Lung C... Stage III Lung ... Unresectable Lu... | Accelerated Hyp... Biospecimen Col... Computed Tomogr... Durvalumab Magnetic Resona... Monalizumab Oleclumab Radiation Thera... | 18 Years - | National Cancer Institute (NCI) | |
| A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies | NCT02740985 | Advanced Solid ... Non-Small Cell ... Metastatic Cast... Colorectal Carc... | AZD4635 Durvalumab Abiraterone Ace... Enzalutamide Oleclumab Docetaxel | 18 Years - 130 Years | AstraZeneca | |
| A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Pancreatic Adenocarcinoma, Non-Small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck to Correlate Clinical, Molecular and Immunologic Parameters With DNA Methylation | NCT04262388 | Pancreatic Duct... Non-small Cell ... Squamous Cell C... | Durvalumab Oleclumab | 18 Years - | University Health Network, Toronto | |
| IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors. | NCT04261075 | Advanced Solid ... | IPH5201 durvalumab oleclumab | 18 Years - 101 Years | MedImmune LLC | |
| Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer | NCT03794544 | Resectable Early-stage NSCLC | Durvalumab Oleclumab Monalizumab Danvatirsen | 18 Years - 102 Years | MedImmune LLC | |
| Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer | NCT03794544 | Resectable Early-stage NSCLC | Durvalumab Oleclumab Monalizumab Danvatirsen | 18 Years - 102 Years | MedImmune LLC | |
| A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer | NCT05221840 | Non-Small Cell ... | Durvalumab Oleclumab Monalizumab Placebo | 18 Years - | AstraZeneca | |
| MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study. | NCT03611556 | Carcinoma Metastatic Panc... | Oleclumab Durvalumab Gemcitabine Nab-paclitaxel Oxaliplatin Folinic acid 5-FU | 18 Years - 101 Years | MedImmune LLC |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
